Epigenetics in cancer therapy and nanomedicine
Abstract The emergence of nanotechnology applied to medicine has revolutionized the treatment of human cancer. As in the case of classic drugs for the treatment of cancer, epigenetic drugs have evolved in terms of their specificity and efficiency, especially because of the possibility of using more...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | Clinical Epigenetics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13148-019-0675-4 |
id |
doaj-819b3afd3916467a808f27d87263f9be |
---|---|
record_format |
Article |
spelling |
doaj-819b3afd3916467a808f27d87263f9be2020-11-24T21:30:32ZengBMCClinical Epigenetics1868-70751868-70832019-05-0111111810.1186/s13148-019-0675-4Epigenetics in cancer therapy and nanomedicineAnnalisa Roberti0Adolfo F. Valdes1Ramón Torrecillas2Mario F. Fraga3Agustin F. Fernandez4Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), ISPA-FINBA-Hospital Universitario Central de Asturias HUCA, Universidad de OviedoNanomaterials and Nanotechnology Research Center (CINN-CSIC)-Universidad de Oviedo-Principado de AsturiasNanomaterials and Nanotechnology Research Center (CINN-CSIC)-Universidad de Oviedo-Principado de AsturiasNanomaterials and Nanotechnology Research Center (CINN-CSIC)-Universidad de Oviedo-Principado de AsturiasCancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), ISPA-FINBA-Hospital Universitario Central de Asturias HUCA, Universidad de OviedoAbstract The emergence of nanotechnology applied to medicine has revolutionized the treatment of human cancer. As in the case of classic drugs for the treatment of cancer, epigenetic drugs have evolved in terms of their specificity and efficiency, especially because of the possibility of using more effective transport and delivery systems. The use of nanoparticles (NPs) in oncology management offers promising advantages in terms of the efficacy of cancer treatments, but it is still unclear how these NPs may be affecting the epigenome such that safe routine use is ensured. In this work, we summarize the importance of the epigenetic alterations identified in human cancer, which have led to the appearance of biomarkers or epigenetic drugs in precision medicine, and we describe the transport and release systems of the epigenetic drugs that have been developed to date.http://link.springer.com/article/10.1186/s13148-019-0675-4EpigeneticsDNMT inhibitorsHDCA inhibitorsNanomedicineNanoparticlesNanocarriers |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Annalisa Roberti Adolfo F. Valdes Ramón Torrecillas Mario F. Fraga Agustin F. Fernandez |
spellingShingle |
Annalisa Roberti Adolfo F. Valdes Ramón Torrecillas Mario F. Fraga Agustin F. Fernandez Epigenetics in cancer therapy and nanomedicine Clinical Epigenetics Epigenetics DNMT inhibitors HDCA inhibitors Nanomedicine Nanoparticles Nanocarriers |
author_facet |
Annalisa Roberti Adolfo F. Valdes Ramón Torrecillas Mario F. Fraga Agustin F. Fernandez |
author_sort |
Annalisa Roberti |
title |
Epigenetics in cancer therapy and nanomedicine |
title_short |
Epigenetics in cancer therapy and nanomedicine |
title_full |
Epigenetics in cancer therapy and nanomedicine |
title_fullStr |
Epigenetics in cancer therapy and nanomedicine |
title_full_unstemmed |
Epigenetics in cancer therapy and nanomedicine |
title_sort |
epigenetics in cancer therapy and nanomedicine |
publisher |
BMC |
series |
Clinical Epigenetics |
issn |
1868-7075 1868-7083 |
publishDate |
2019-05-01 |
description |
Abstract The emergence of nanotechnology applied to medicine has revolutionized the treatment of human cancer. As in the case of classic drugs for the treatment of cancer, epigenetic drugs have evolved in terms of their specificity and efficiency, especially because of the possibility of using more effective transport and delivery systems. The use of nanoparticles (NPs) in oncology management offers promising advantages in terms of the efficacy of cancer treatments, but it is still unclear how these NPs may be affecting the epigenome such that safe routine use is ensured. In this work, we summarize the importance of the epigenetic alterations identified in human cancer, which have led to the appearance of biomarkers or epigenetic drugs in precision medicine, and we describe the transport and release systems of the epigenetic drugs that have been developed to date. |
topic |
Epigenetics DNMT inhibitors HDCA inhibitors Nanomedicine Nanoparticles Nanocarriers |
url |
http://link.springer.com/article/10.1186/s13148-019-0675-4 |
work_keys_str_mv |
AT annalisaroberti epigeneticsincancertherapyandnanomedicine AT adolfofvaldes epigeneticsincancertherapyandnanomedicine AT ramontorrecillas epigeneticsincancertherapyandnanomedicine AT marioffraga epigeneticsincancertherapyandnanomedicine AT agustinffernandez epigeneticsincancertherapyandnanomedicine |
_version_ |
1725963006499618816 |